Global Herd Immunity Against COVID-19 Unlikely, Says Ebola Vaccine Developer
Leverage Labor Diversity, Tech
As coronavirus variants keep emerging, global herd immunity is unlikely, says Steven Jones, one of the developers of the first Ebola vaccine. In a wide-ranging discussion with McKinsey, he and other experts weighed in on ways to live with COVID-19, which is expected to soon become endemic.
You may also be interested in...
While a Star Health study found high hospitalization costs for COVID-19 patients in India, those vaccinated paid 24% less and faced 81% lower mortality risk. However, insurers are unlikely to offer lower premiums to those vaccinated, even as the prospects for an overall hike remain uncertain, say experts.
In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.
Studies point to Johnson & Johnson, Pfizer and Bharat Biotech’s vaccines neutralizing the Delta variant of SARS-CoV-2, even if efficacy is lower compared to the original strain. This follows positive news from other vaccine companies but will the Lambda variant cause a setback?